Pharmacokinetic-pharmacodynamic modelling of behavioural responses

被引:10
|
作者
Della Paschoa, OE
Kruk, MR
Danhof, M
机构
[1] Leiden Amsterdam Ctr Drug Res, Div Pharmacol, NL-2300 RA Leiden, Netherlands
[2] Leiden Amsterdam Ctr Drug Res, Div Med Pharmacol, Ethopharmacol Grp, NL-2300 RA Leiden, Netherlands
来源
关键词
PK/PD modelling; behavioural measures; data acquisition; ethopharmacology; ultrasonic vocalizations; buspirone; concentration-effect relationship;
D O I
10.1016/S0149-7634(98)00023-2
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Drug concentrations at the site of action in studies on behavioural pharmacology, are seldom constant. Therefore, observed changes in behaviour can be due to the natural time course of behavioural processes, but equally to changes in drug concentration, and it is therefore crucial to separate the former from the latter. One solution is keeping drug concentrations constant. However, one can also exploit the variation in drug concentration caused by absorption, distribution and elimination of a drug. This is done by simultaneous measurement of drug effect and concentration, while the drug enters and leaves a biologically relevant compartment, such as blood or cerebrospinal fluid. The concept of determining concentration-effect curves in individual animals, by monitoring in parallel drug effect and changes in concentration in one single experiment, has not yet found wide application in behavioural studies. The fact that behavioural processes, like any other physiological process, change over time, may have contributed to the scarcity of pharmacokinetic-pharmacodynamic (PK/PD) studies in behavioural pharmacology. However, there are now mathematical techniques that allow PK/PD modelling even if the effect parameter changes over time or cannot be properly assessed in every instance. Here we use PK/PD modelling to characterize fear-induced ultrasonic vocalizations and the anxiolytic effect of buspirone. This approach reduces the number of animals required to assess concentration-effect relationships. More importantly, it allows the identification of differences in individual drug response over a wide range of concentrations. Consequently, we suggest that PK/PD modelling can be used as a tool to study drug-induced changes in behavioural response. An introduction in PK/PD modelling is presented. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:229 / 236
页数:8
相关论文
共 50 条
  • [31] PHARMACOKINETIC-PHARMACODYNAMIC MODELING IN PAIN
    Loetsch, J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 14 - 14
  • [32] Pharmacokinetic-Pharmacodynamic Modelling of Ketamine in Six Neurotraumatised Intensive Care Patients
    Youssef Hijazi
    Carole Bodonian
    François Salord
    Françoise Bressolle
    Roselyne Boulieu
    Clinical Drug Investigation, 2003, 23 : 605 - 609
  • [33] A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine
    Urien, S
    Tillement, JP
    Ganem, B
    Kuch, MD
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1999, 37 (10) : 499 - 502
  • [34] Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses
    Friberg, LE
    Isbister, GK
    Duffull, SB
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (02) : 177 - 190
  • [35] Pharmacokinetic-Pharmacodynamic Modelling of the Antipyretic Effect of Two Oral Formulations of Ibuprofen
    Iñaki F. Trocóniz
    Santos Armenteros
    María V. Planelles
    Julio Benítez
    Rosario Calvo
    Rosa Domínguez
    Clinical Pharmacokinetics, 2000, 38 : 505 - 518
  • [36] Pharmacokinetic-pharmacodynamic modelling of the antinociceptive effect of a romifidine infusion in standing horses
    Bernal, Sabina Diez
    Studer, Nicole
    Thormann, Wolfgang
    Spadavecchia, Claudia
    Levionnois, Olivier
    VETERINARY ANAESTHESIA AND ANALGESIA, 2020, 47 (01) : 129 - 136
  • [37] Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations
    Brill, M. J. E.
    Kristoffersson, A. N.
    Zhao, C.
    Nielsen, E. I.
    Friberg, L. E.
    CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 (07) : 697 - 706
  • [38] Pharmacokinetic-Pharmacodynamic Modelling of Recombinant Human Erythropoietin in AthletesA Population Approach
    A. Gaudard
    E. Varlet-Marie
    M. Audran
    R. Gomeni
    F. Bressolle
    Clinical Drug Investigation, 2003, 23 : 167 - 179
  • [39] Pharmacokinetic-pharmacodynamic modelling and simulation of methotrexate dosing in patients with rheumatoid arthritis
    Tan, Jiun Ming
    Upton, Richard N.
    Foster, David J. R.
    Proudman, Susanna M.
    Dhir, Varun
    Wiese, Michael D.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (11) : 2763 - 2780
  • [40] Pharmacokinetic-pharmacodynamic modelling to investigate herb-drug interactions with warfarin
    Jiang, X
    Williams, KM
    Liauw, W
    Ammit, AJ
    Roufogalis, BD
    Duke, CC
    Day, RO
    McLachlan, AJ
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (11) : A227 - A227